Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176420
Title: | Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial |
Author: | López Miranda, Elena Pérez García, José Manuel Cosimo, Serena Di Brain, Etienne Ravnik, Maja Escrivá de Romaní, Santiago Vidal Losada, Maria Jesús Gligorov, Joseph Borstnar, Simona Calabuig, Laura Sampayo-Cordero, Miguel Malfettone, Andrea Llombart Cussac, Antonio Suter, Thomas M. Cortés, Javier |
Keywords: | Càncer de mama Metàstasi Breast cancer Metastasis |
Issue Date: | 1-Dec-2020 |
Publisher: | MDPI |
Abstract: | The paper assesses the dose-limiting toxicities and the maximum tolerated dose (MTD) of trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal doxorubicin (NPLD) in HER2-positive (HER2+) metastatic breast cancer (MBC). This single-arm, open-label, phase Ib trial (NCT02562378) enrolled anthracycline-naïve HER2+ MBC patients who had progressed on trastuzumab and taxanes. Patients received a maximum of 6 cycles of NPLD intravenously (IV) at various dose levels (45, 50, and 60 mg/m2) in the "3 plus 3" dose-escalation part. During expansion, they received 60 mg/m2 of NPLD every 3 weeks (Q3W) plus standard doses of T-DM1. The MTD was T-DM1 3.6 mg/kg plus NPLD 60 mg/m2 administered IV Q3W. No clinically relevant worsening of cardiac function was observed. Among all evaluable patients, the overall response rate was 40.0% (95%CI, 16.3-67.7) with a median duration of response of 6.9 months (95%CI, 4.8-9.1). Clinical benefit rate was 66.7% (95%CI, 38.4-88.2) and median progression-free survival was 7.2 months (95%CI, 4.5-9.6). No significant influence of NPLD on T-DM1 pharmacokinetics was observed. The addition of NPLD to T-DM1 is feasible but does not seem to improve the antitumor efficacy of T-DM1 in HER2+ MBC patients. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cancers12123509 |
It is part of: | Cancers, 2020, vol. 12, num. 12 |
URI: | http://hdl.handle.net/2445/176420 |
Related resource: | https://doi.org/10.3390/cancers12123509 |
ISSN: | 2072-6694 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
709546.pdf | 1.05 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License